JPMorgan Chase & Co. Initiates Coverage on Odyssey Therapeutics (NASDAQ:ODTX)

Research analysts at JPMorgan Chase & Co. initiated coverage on shares of Odyssey Therapeutics (NASDAQ:ODTX) in a research note issued to investors on Tuesday. The firm set an “overweight” rating and a $26.00 price target on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 53.30% from the company’s previous close.

A number of other brokerages have also issued reports on ODTX. Wedbush assumed coverage on shares of Odyssey Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $30.00 price target on the stock. Oppenheimer assumed coverage on shares of Odyssey Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $40.00 price target on the stock. TD Cowen assumed coverage on shares of Odyssey Therapeutics in a report on Tuesday. They issued a “buy” rating on the stock. Cantor Fitzgerald assumed coverage on shares of Odyssey Therapeutics in a report on Tuesday. They issued an “overweight” rating on the stock. Finally, Wall Street Zen raised shares of Odyssey Therapeutics to a “hold” rating in a report on Saturday, May 16th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Odyssey Therapeutics has a consensus rating of “Buy” and a consensus target price of $32.00.

Odyssey Therapeutics Price Performance

Shares of Odyssey Therapeutics stock opened at $16.96 on Tuesday. Odyssey Therapeutics has a 12-month low of $15.35 and a 12-month high of $20.30.

Insider Buying and Selling

In other Odyssey Therapeutics news, major shareholder Sr One Capital Management, Llc purchased 555,555 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $9,999,990.00. Following the purchase, the insider directly owned 1,831,383 shares in the company, valued at $32,964,894. The trade was a 43.54% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Dimension Capital Ii, L.P. purchased 1,111,111 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was acquired at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the completion of the purchase, the director owned 3,333,516 shares in the company, valued at $60,003,288. This represents a 50.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 4,183,777 shares of company stock worth $75,319,986 over the last 90 days.